Navigation Links
Advancing Research to Therapies for Brain Tumors Conference Connects Academic Scientists to Industry Investors
Date:7/23/2013

BOSTON, MA (PRWEB) July 23, 2013

National Brain Tumor Society, the largest nonprofit in the United States dedicated to the brain tumor community, recently hosted the inaugural Advancing Research to Therapies (ART) for Brain Tumors Conference in Washington, D.C. The ART Conference brought together more than 100 leading experts from academic research labs, government agencies, biotech and pharmaceutical companies, and venture capital firms to increase communication and collaboration, as well as discuss licensing and investment criteria for new drug candidates to speed the discovery of new treatments for brain tumor patients.

“With very few exceptions, the different stakeholders involved in brain tumor drug development don’t discuss the barriers they face, their particular needs and wants, and thus what needs to, and can, happen to get new and better therapies to patients,” said N. Paul TonThat, Executive Director, National Brain Tumor Society. “This was an unique opportunity to get everyone in a room, get all the issues on the table, and plot a course forward.”

Sponsored by Morgan, Lewis & Bockius LLP and BioHealth Innovation, the Conference engaged attendees, as well as participants, in a discussion surrounding the issues and criteria for advancing discoveries from academic labs, through the commercialization process, and into the hands of clinicians and patients. Specifically, audience and panelists sought to better understand why more treatments for brain tumors aren’t available despite recent gains in research.

To address the issues effecting brain tumor therapeutic development, three panels of experts shared their distinct perspectives on the R&D process:

  • VC Panel: Venture capitalists shared their conditions for determining whether to invest in a company, academic asset, or drug candidate
  • BioPharma Panel: Biotech and pharmaceutical company executives shared their criteria for determining whether to license and develop an academic asset or drug candidate
  • Federal Government Resources Panel: Employees from the National Institutes of Health/National Institute for Neurological Disease and Stroke outlined resources available for brain tumor researchers, in terms of both funding and advice, to translate discoveries into therapies

The panels discussed issues ranging from creating data packages big enough to show translatability and reproducibility (close to 70% of research fails to reproduce outside the original academic lab), to de-risking and simplifying the market for brain tumor drug development. Panelists also offered candid advice for researchers.

"If you're an academic looking to potentially take a program or an asset from your lab and trying to spin it out into a company, it's important as you begin to look at possible investors that you understand what their investment strategy is," said Michael Gutch, PhD, MD, and Managing Director of MedImmune Ventures.

"We invest in people we like to invest with,” added Neil Exter, Partner, Third Rock Ventures. “It's good to develop relationships with your friendly VCs in the nearer term, or over time."

Following the advice and subsequent discussions from Industry and government’s perspective, National Brain Tumor Society-funded academic researchers showcased their latest drug candidates in hopes of obtaining funding to move their asset toward clinical trials. Out of the four drug candidates presented, two of the corresponding researchers have already been in deeper discussions with Industry representatives that were on hand to seek licensing and development partnerships.

Nearly 700,000 people in the U.S. are living with a brain tumor, and close to 14,000 people will die because of the disease this year alone. Only one out of three adults diagnosed with a malignant brain tumor today will be alive in five years. More so than any other cancer, a brain tumor can have life-altering psychological, cognitive, behavioral, and physical effects. Yet, there are only four FDA approved drugs to treat brain tumors; only one is used in standard of care.

Panelists at the event included executives from SR One, Third Rock Ventures, MedImmune Ventures, Genentech/Roche, Pfizer, and Health Advances.

Medical academics presenting drug candidates included researchers from MD Anderson Cancer Center, Duke University, and University of Alabama Birmingham.

To learn more about the event and view/download presentations, please visit: http://www.braintumor.org/ART

About National Brain Tumor Society
National Brain Tumor Society is the largest nonprofit organization dedicated to the brain tumor community in the United States. We are fiercely committed to finding better treatments, and ultimately a cure, for people living with a brain tumor today and those who will be diagnosed tomorrow. This means aggressively driving strategic research and advocating for public policies, which meet the critical needs of this community. To learn more visit http://www.braintumor.org

Read the full story at http://www.prweb.com/releases/2013/7/prweb10921209.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA
2. Advancing Preclinical Predictions, Making Faster Clinical Decisions with Cancer Models and Preclinical Imaging - World Pharma Congress this June in Philadelphia
3. 4th Annual Advancing Global Clinical Trials Conference is Announced
4. Astute Medical, Inc. Advancing Next Generation Acute Kidney Injury Biomarkers
5. CureLauncher is Described on LIVESTRONG Blog as Modern Platform That Gets People Involved in Advancing New Cancer Treatments
6. GenoSpace Announces the Launch of a Cloud-Based "Information Ecosystem" for Advancing 21st-Century Personalized Medicine
7. QIAGEN Partners with Exosome Diagnostics to Create High-Performance Biofluid Sample Preparation Kits for Personalized Healthcare Research
8. Medical Device and Drug Research, New Life Science Webinar Hosted by Xtalks
9. Global Activated Carbon Market 2012-2016: Latest Market Share, Growth, Analysis, Size, Trends & Forecast Research Report 2012-2016 Available at Marketresearchreports.biz
10. Elliott Broidy Expands Role in Los Angeles Civics with Support of Stem Cell Research Program
11. New Research on Rapid Identification and Strain Typing of Salmonella in Food to Be Presented at IAFP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Germany and GERMANTOWN, Maryland ... ; Frankfurt Prime Standard: QIA) today announced the introduction ... for gene expression profiling, expanding QIAGEN,s portfolio of Sample ... enable researchers to select from over 20,000 human genes ... interactions between genes, cellular phenotypes and disease processes. ...
(Date:2/11/2016)... -- Spectra BioPharma Selling Solutions (Spectra) is a new ... the experience, expertise, operational delivery and customer focus ... Created in concert with industry leading commercial experts, ... tactical needs of its clients by providing value-based ... and non-personal promotion. --> ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... to delivering cutting-edge information focused on the development and manufacture of biopharmaceuticals ... a premier sponsor of the 2016 BioProcess International Awards – Recognizing Excellence ...
(Date:2/11/2016)... Florida , February 11, 2016 ... PositiveID Corporation ("PositiveID" or "Company") (OTCQB: PSID), a ... announced today that its Thermomedics subsidiary, which markets ... on its growth plan in January 2016, including ... distributors, increasing sequential monthly sales growth, and establishing ...
Breaking Biology Technology:
(Date:2/2/2016)... 2, 2016  BioMEMS devices deployed in ... on medical screening and diagnostic applications, such ... devices that facilitate and assure continuous monitoring ... are being bolstered through new opportunities offered ... acquisition coupled with wireless connectivity and low ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 Technology ... service presents an analysis of the digital and computed ... Malaysia , and Indonesia ... current trends and market size, as well as regional ... by country and discusses market penetration and market attractiveness, ...
(Date:2/1/2016)... BURNABY, Canada , February 1, 2016 ... new technological advancements to drive global touchfree intuitive gesture ...   --> Rising sales of consumer electronics ... intuitive gesture control market size ... of consumer electronics coupled with new technological advancements to ...
Breaking Biology News(10 mins):